



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

October 8, 2014

CARDIOCOMM SOLUTIONS, INC. CONFIRMS VENDOR CLEARANCE FOR SALES INTO U.S. FEDERAL GOVERNMENT AGENCIES AND ARMED FORCES

GEMS™ WIN Software and HeartCheck™ Sales Will Have Expanded Access into the United States Air Force and Other Military Establishments

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") CardioComm Solutions today announced that it has become an approved vendor for the sale of their HeartCheck™ products and ECG-based software solutions into numerous organizations within the umbrella of the U.S. Federal Government. As an active registrar in the U.S. Federal Government's System for Award Management (SAM), CardioComm Solutions is now eligible for contracts, assistance awards and to do business with the U.S. Federal Government and their agencies globally.

The approval process requires several levels of reviews from organizations such as Dun & Bradstreet, the Department of Defense's Defense Logistics Agency and the Internal Revenue Service. As a non-US based organization, the Company also secured a NATO Commercial & Government Entity Code (NCAGE) which is used extensively in various procurement, codification and logistics functions throughout the Federal Government as well as by over 20 countries worldwide. One of its primary purposes is to identify potential sources of supply for items being acquired by the military forces of these countries.

The expanded exposure for the sales of CardioComm Solutions GEMS™ WIN and HeartCheck™ ECG products opens up an important sector within the U.S. market. Following the finalization of CardioComm Solutions' approval, the Company confirms the first SAM-based sale of its recently released GEMS™ software into a U.S. Military Medical Centre located in Europe. The current disclosure follows closely a recent press release announcing CardioComm Solutions' listing by the FAA Civil Aerospace Medical Institute as an ECG Cloud Service provider for use by Air Medical Examiners.

CardioComm Solutions' executive management confirms that additional GEMS™ WIN license purchase reviews are underway within U.S. Federal Military bases and medical centers and that they are working with additional departments within the U.S. Military and Veteran Affairs for securing further approvals and preferred vendor status clearances. Further updates will be provided by the Company.

To learn more about the CardioComm Solutions products please see the Company's website www.cardiocommsolutions.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

For more information please contact investorrelations@cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should: specifically consider risks discussed under the heading "Risk Factors" in the Company's Annual Information Form, available at www.sedar.com; not to place undue reliance on forward-looking statements and forward-looking information; be aware the Company does not assume any obligation to update the



forward-looking statements and forward-looking information contained in this Annual Information Form other than as required by applicable laws (including without limitation Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*)).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.